Centessa Pharmaceuticals Announces Poster Presentation of New Preclinical Data Supporting Expansion of Orexin Receptor 2 (OX2R) Agonist Pipeline into Neuropsychiatric Indications at the 64th ACNP Annual Meeting

Summary by AI BETAClose X

Centessa Pharmaceuticals announced preclinical data presented at the 64th ACNP Annual Meeting demonstrating that its OX2R agonist, CNT-9982, reduced behavioral despair and enhanced wakefulness in an animal model of major depressive disorder, supporting its potential for neuropsychiatric indications beyond rare hypersomnias. These findings reinforce Centessa's strategy to target the orexin pathway for new therapeutic options addressing mood symptoms, excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue across various neuroscience indications. The company is developing a pipeline of OX2R agonists, including ORX750 for sleep-wake disorders and ORX142 and ORX489 for neurological, neurodegenerative, and neuropsychiatric disorders.

Disclaimer*

UK 100

Latest directors dealings